Glenmark Pharmaceuticals Ltd vs Rekvina Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2173 as of 12 Jun 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Rekvina Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Rekvina Labs Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 3959 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the growth of 0.37% The revenue of Rekvina Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 578.28 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -20.77% The ebitda of Rekvina Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 301.32 crore over 8 quarters. This represents a CAGR of -5.89% The net profit of Rekvina Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Rekvina Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Rekvina Labs Ltd

Rekvina Labs Limited was incorporated on 1st November 1988.
From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore.
It is registered in England and Wales as a Public Limited Company.
The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements.
It provide contract research and manufacturing services to customers. The Company is mainly engaged in manufacturing and marketing of pharmaceutical products.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Rekvina Labs Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 61,327 Cr while Market cap of Rekvina Labs Ltd is 23 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd?

As of June 14, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2173.2. On the other hand, Rekvina Labs Ltd stock price is INR ₹39.0.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Rekvina Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.